Cargando…
Inhibition of the potassium channel Kv1.3 reduces infarction and inflammation in ischemic stroke
OBJECTIVE: Inhibitors of the voltage‐gated K(+) channel Kv1.3 are currently in development as immunomodulators for the treatment of autoimmune diseases. As Kv1.3 is also expressed on microglia and has been shown to be specifically up‐regulated on “M1‐like” microglia, we here tested the therapeutic h...
Autores principales: | Chen, Yi‐Je, Nguyen, Hai M., Maezawa, Izumi, Jin, Lee‐Way, Wulff, Heike |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817832/ https://www.ncbi.nlm.nih.gov/pubmed/29468176 http://dx.doi.org/10.1002/acn3.513 |
Ejemplares similares
-
The potassium channel Kv1.3 as a therapeutic target for immunocytoprotection after reperfusion
por: Chen, Yi‐Je, et al.
Publicado: (2021) -
Immunocytoprotection after reperfusion with Kv1.3 inhibitors has an extended treatment window for ischemic stroke
por: Lee, Ruth D., et al.
Publicado: (2023) -
Differential Kv1.3, KCa3.1, and Kir2.1 expression in “classically” and “alternatively” activated microglia
por: Nguyen, Hai M., et al.
Publicado: (2016) -
Biophysical basis for Kv1.3 regulation of membrane potential changes induced by P2X4‐mediated calcium entry in microglia
por: Nguyen, Hai M., et al.
Publicado: (2020) -
A multiplatform strategy for the discovery of conventional monoclonal antibodies that inhibit the voltage-gated potassium channel Kv1.3
por: Bednenko, Janna, et al.
Publicado: (2018)